Literature DB >> 19366830

Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.

Jens Hillengass1, Christian Zechmann, Tobias Bäuerle, Barbara Wagner-Gund, Christiane Heiss, Axel Benner, Anthony Ho, Kai Neben, Dirk Hose, Hans-Ulrich Kauczor, Hartmut Goldschmidt, Stefan Delorme, Thomas Moehler.   

Abstract

PURPOSE: The aim of our study was to investigate whether dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) allows visualization of changes in microcirculation between healthy controls on the one side and early/advanced stages of plasma cell disease on the other. EXPERIMENTAL
DESIGN: We examined a group of 222 individuals consisting of 60 patients with monoclonal gammopathy of undetermined significance (MGUS), 65 patients with asymptomatic multiple myeloma (aMM), 75 patients with newly diagnosed symptomatic MM (sMM), and 22 healthy controls with DCE-MRI of the lumbar spine.
RESULTS: A continuous increase in microcirculation parameters amplitude A and exchange rate constant kep reflecting vascular volume and permeability, respectively, was detected from normal controls over MGUS and aMM to sMM. For A and kep, significant differences were found between controls and aMM (P = 0.03 and P = 0.004, respectively) as well as controls and sMM (P = 0.001 and P < 0.001, respectively). Although diffuse microcirculation patterns were found in healthy controls as well as MGUS and MM, a pattern with focal hotspots was exclusively detected in 42.6% of sMM and in 3 MGUS and 3 aMM patients. MGUS and aMM patients with increased microcirculation patterns showed significantly higher bone marrow plasmocytosis compared with patients with a low microcirculation pattern.
CONCLUSIONS: Our investigations substantiate the concept of an angiogenic switch from early plasma cell disorders to sMM. Pathologic DCE-MRI findings correlate with adverse prognostic factors and DCE-MRI identifies a distinct group of patients with increased microcirculation parameters in aMM and MGUS patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366830     DOI: 10.1158/1078-0432.CCR-08-2310

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

Review 1.  Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements.

Authors:  Gunnar Brix; Jürgen Griebel; Fabian Kiessling; Frederik Wenz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

Review 2.  The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.

Authors:  Jo Caers; Nadia Withofs; Jens Hillengass; Paolo Simoni; Elena Zamagni; Roland Hustinx; Yves Beguin
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 3.  Imaging of multiple myeloma: Current concepts.

Authors:  Thorsten Derlin; Peter Bannas
Journal:  World J Orthop       Date:  2014-07-18

Review 4.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.

Authors:  Neha Korde; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Blood       Date:  2011-03-25       Impact factor: 22.113

5.  Differentiation of tuberculosis and metastatic cancer in the spine using dynamic contrast-enhanced MRI.

Authors:  Ning Lang; Min-Ying Su; Hon J Yu; Huishu Yuan
Journal:  Eur Spine J       Date:  2015-03-08       Impact factor: 3.134

Review 6.  Myelomagenesis: capturing early microenvironment changes.

Authors:  Neha Korde; Irina Maric
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 7.  Functional and molecular MRI of the bone marrow in multiple myeloma.

Authors:  Vassilis Koutoulidis; Nickolas Papanikolaou; Lia A Moulopoulos
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

8.  Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial.

Authors:  M Bhutani; B Turkbey; E Tan; T J Kemp; L A Pinto; A R Berg; N Korde; A R Minter; B M Weiss; E Mena; L Lindenberg; O Aras; M P Purdue; J N Hofmann; S M Steinberg; K R Calvo; P L Choyke; I Maric; K Kurdziel; O Landgren
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

Review 9.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

10.  Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.

Authors:  Maximilian Merz; Thomas M Moehler; Judith Ritsch; Tobias Bäuerle; Christian M Zechmann; Barbara Wagner; Anna Jauch; Dirk Hose; Christina Kunz; Thomas Hielscher; Hendrik Laue; Hartmut Goldschmidt; Stefan Delorme; Jens Hillengass
Journal:  Eur Radiol       Date:  2015-07-29       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.